GSK looks to expand into MM subsets after submitting first anti-BCMA BLA

GSK is the first company out of the gate with a regulatory submission for a BCMA-targeted therapy. The ADC’s most recent response rates are lower than many programs from competing modalities against the same target reported this month, but the company is using its head start to rapidly move into early-line settings.

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) reported full data for the pivotal DREAMM-2 trial of its antibody-drug conjugate belantamab mafodotin (GSK2857916) in The Lancet Oncology on Monday. A 2.5 mg/kg dose produced a 31% overall response rate in relapsed and refractory multiple myeloma patients who received a median of seven prior lines of treatment...